799 related articles for article (PubMed ID: 31310175)
41. Prevalence of different LI-RADS v2018 categories in high-risk patients undergoing CT- or MRI-based screening for hepatocellular carcinoma.
Shahbazian H; Birnbaum J; Burns PJ; Shabanan SH; Kanmaniraja D; Reinus J; Kamel I; Sirlin CB; Chernyak V
Abdom Radiol (NY); 2023 Dec; 48(12):3696-3702. PubMed ID: 37725110
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.
Seo N; Kim MS; Park MS; Choi JY; Do RKG; Han K; Kim MJ
Eur Radiol; 2020 Jan; 30(1):261-271. PubMed ID: 31418085
[TBL] [Abstract][Full Text] [Related]
43. Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS.
Schellhaas B; Görtz RS; Pfeifer L; Kielisch C; Neurath MF; Strobel D
Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1036-1044. PubMed ID: 28562394
[TBL] [Abstract][Full Text] [Related]
44. Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging.
Lee S; Kim SS; Chang DR; Kim H; Kim MJ
Clin Mol Hepatol; 2020 Jul; 26(3):340-351. PubMed ID: 32492765
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of LI-RADS Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma in Liver Transplant Candidates: Intraindividual Comparison between CT and Hepatobiliary Agent-enhanced MRI.
Bae JS; Lee JM; Yoon JH; Kang HJ; Jeon SK; Joo I; Lee KB; Kim H
Radiology; 2021 May; 299(2):336-345. PubMed ID: 33650901
[TBL] [Abstract][Full Text] [Related]
46. Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018.
Ludwig DR; Fraum TJ; Cannella R; Ballard DH; Tsai R; Naeem M; LeBlanc M; Salter A; Tsung A; Shetty AS; Borhani AA; Furlan A; Fowler KJ
Abdom Radiol (NY); 2019 Jun; 44(6):2116-2132. PubMed ID: 30798397
[TBL] [Abstract][Full Text] [Related]
47. Profiling hepatocellular carcinoma aggressiveness with contrast-enhanced ultrasound and gadoxetate disodium-enhanced MRI: An intra-individual comparative study based on the Liver Imaging Reporting and Data System.
Yang J; Jiang H; Xie K; Bashir MR; Wan H; Huang J; Qin Y; Chen J; Lu Q; Song B
Eur J Radiol; 2022 Sep; 154():110397. PubMed ID: 35696735
[TBL] [Abstract][Full Text] [Related]
48. How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?
Lee HS; Kim MJ; An C
Eur Radiol; 2019 May; 29(5):2408-2416. PubMed ID: 30552477
[TBL] [Abstract][Full Text] [Related]
49. Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features.
Jiang H; Song B; Qin Y; Chen J; Xiao D; Ha HI; Liu X; Oloruntoba-Sanders O; Erkanli A; Muir AJ; Bashir MR
Eur Radiol; 2021 Jun; 31(6):3638-3648. PubMed ID: 33245494
[TBL] [Abstract][Full Text] [Related]
50. A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions.
Min JH; Kim JM; Kim YK; Kim H; Choi GS; Kang TW; Cha D; Hwang JA; Ko SE; Ahn S
Eur Radiol; 2022 Feb; 32(2):912-922. PubMed ID: 34345947
[TBL] [Abstract][Full Text] [Related]
51. Individual Participant Data Meta-Analysis of LR-5 in LI-RADS Version 2018 versus Revised LI-RADS for Hepatocellular Carcinoma Diagnosis.
Goins SM; Jiang H; van der Pol CB; Salameh JP; Lam E; Adamo RG; McInnes MDF; Costa AF; Tang A; Alhasan AS; Allen BC; Reiner CS; Clarke C; Cerny M; Wang J; Choi SH; Fraum TJ; Ludwig DR; Song B; Joo I; Kang Z; Kierans AS; Kim SY; Kwon H; Ronot M; Podgórska J; Rosiak G; Song JS; Bashir MR
Radiology; 2023 Dec; 309(3):e231656. PubMed ID: 38112549
[TBL] [Abstract][Full Text] [Related]
52. LI-RADS: Diagnostic Performance of Hepatobiliary Phase Hypointensity and Major Imaging Features of LR-3 and LR-4 Lesions Measuring 10-19 mm With Arterial Phase Hyperenhancement.
Vernuccio F; Cannella R; Meyer M; Choudhoury KR; Gonzáles F; Schwartz FR; Gupta RT; Bashir MR; Furlan A; Marin D
AJR Am J Roentgenol; 2019 Aug; 213(2):W57-W65. PubMed ID: 31039012
[No Abstract] [Full Text] [Related]
53. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.
Terzi E; Iavarone M; Pompili M; Veronese L; Cabibbo G; Fraquelli M; Riccardi L; De Bonis L; Sangiovanni A; Leoni S; Zocco MA; Rossi S; Alessi N; Wilson SR; Piscaglia F;
J Hepatol; 2018 Mar; 68(3):485-492. PubMed ID: 29133247
[TBL] [Abstract][Full Text] [Related]
54. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features.
Kim SW; Joo I; Kim HC; Ahn SJ; Kang HJ; Jeon SK; Lee JM
Eur Radiol; 2020 May; 30(5):2861-2870. PubMed ID: 32006170
[TBL] [Abstract][Full Text] [Related]
55. Prevalence and clinical significance of discordant LI-RADS
Yokoo T; Singal AG; Diaz de Leon A; Ananthakrishnan L; Fetzer DT; Pedrosa I; Khatri G
Abdom Radiol (NY); 2020 Jan; 45(1):177-187. PubMed ID: 31342103
[TBL] [Abstract][Full Text] [Related]
56. Liver imaging reporting and data system diagnostic performance in hepatocellular carcinoma when modifying the definition of "washout" on gadoxetic acid-enhanced magnetic resonance imaging.
Hu W; Lyu R; Wang D; Gao Z; Sun C; Jia K
Arab J Gastroenterol; 2024 Feb; 25(1):58-63. PubMed ID: 38245474
[TBL] [Abstract][Full Text] [Related]
57. Optimal lexicon of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of hepatocellular carcinoma modified from LI-RADS.
Hwang SH; Park S; Han K; Choi JY; Park YN; Park MS
Abdom Radiol (NY); 2019 Sep; 44(9):3078-3088. PubMed ID: 31165907
[TBL] [Abstract][Full Text] [Related]
58. Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LI-RADS).
Chernyak V; Fowler KJ; Heiken JP; Sirlin CB
J Magn Reson Imaging; 2019 May; 49(5):1236-1252. PubMed ID: 30609194
[TBL] [Abstract][Full Text] [Related]
59. Comparison of gadoxetic acid versus gadopentetate dimeglumine for the detection of hepatocellular carcinoma at 1.5 T using the liver imaging reporting and data system (LI-RADS v.2017).
Ding Y; Rao SX; Wang WT; Chen CZ; Li RC; Zeng M
Cancer Imaging; 2018 Dec; 18(1):48. PubMed ID: 30526674
[TBL] [Abstract][Full Text] [Related]
60. Should Threshold Growth Be Considered a Major Feature in the Diagnosis of Hepatocellular Carcinoma Using LI-RADS?
Park JH; Chung YE; Seo N; Choi JY; Park MS; Kim MJ
Korean J Radiol; 2021 Oct; 22(10):1628-1639. PubMed ID: 34269533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
